| Lacey M Fisk, LCSW | |
|
7818 Moline Rd, Webster, WI 54893-8545 | |
| (715) 866-8301 | |
| (715) 866-8374 |
| Full Name | Lacey M Fisk |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 7818 Moline Rd, Webster, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457696288 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 8011-123 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lacey M Fisk, LCSW 203 United Way Drive, Frederic, WI 54837-8938 Ph: (715) 327-4322 | Lacey M Fisk, LCSW 7818 Moline Rd, Webster, WI 54893-8545 Ph: (715) 866-8301 |
News Archive
Chronic back pain is the leading cause of disability worldwide. In the United States, patients spend up to $300 billion each year to treat the condition, according to a 2012 study published in the Journal of Pain.
Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company's 2009 financial results. The company's Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.
› Verified 5 days ago
Ms. Ana Flora Trepania Winton, MSW, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4404 State Road 70, Webster, WI 54893 Phone: 715-349-8554 Fax: 715-349-8528 |